These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24410536)

  • 21. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ustekinumab for psoriasis and psoriatic arthritis.
    Goldminz AM; Gottlieb AB
    J Rheumatol Suppl; 2012 Jul; 89():86-9. PubMed ID: 22751602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab for the treatment of psoriatic arthritis.
    Chandler DJ; Bewley A
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):111-21. PubMed ID: 24494794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological and synthetic target DMARDs in psoriatic arthritis.
    Silvagni E; Bortoluzzi A; Ciancio G; Govoni M
    Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract]   [Full Text] [Related]  

  • 27. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
    de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
    Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha inhibitors in dermatology.
    Cordoro KM; Feldman SR
    Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab for the treatment of Crohn's disease.
    Khanna R; Feagan BG
    Immunotherapy; 2013 Aug; 5(8):803-15. PubMed ID: 23902548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab in the treatment of moderate-to-severe plaque psoriasis.
    López-Sánchez C; Puig L
    Immunotherapy; 2020 Apr; 12(6):355-371. PubMed ID: 32314622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
    Silva LC; Ortigosa LC; Benard G
    Immunotherapy; 2010 Nov; 2(6):817-33. PubMed ID: 21091114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of ustekinumab in autoimmune disease.
    Ryan C; Thrash B; Warren RB; Menter A
    Expert Opin Biol Ther; 2010 Apr; 10(4):587-604. PubMed ID: 20218921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine-based therapy in psoriasis.
    Mitra A; Fallen RS; Lima HC
    Clin Rev Allergy Immunol; 2013 Apr; 44(2):173-82. PubMed ID: 22426927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
    Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB
    Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ustekinumab in psoriatic arthritis and related phenotypes.
    Dobbin-Sears I; Roberts J; O'Rielly DD; Rahman P
    Ther Adv Chronic Dis; 2018 Oct; 9(10):191-198. PubMed ID: 30263103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab: A Review in Moderate to Severe Crohn's Disease.
    Lamb YN; Duggan ST
    Drugs; 2017 Jul; 77(10):1105-1114. PubMed ID: 28528528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel biological target for the treatment of psoriatic arthritis.
    Spadaro A; Montepaone M; Lubrano E
    Immunotherapy; 2014; 6(5):515-8. PubMed ID: 24896622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab in psoriatic arthritis: need for studies from real-world evidence.
    Queiro R; Coto-Segura P
    Expert Opin Biol Ther; 2018 Sep; 18(9):931-935. PubMed ID: 30044656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.